Free Trial
OTCMKTS:INTI

Inhibitor Therapeutics 3/29/2024 Earnings Report

Inhibitor Therapeutics logo
$0.06 +0.01 (+21.38%)
As of 04/25/2025 12:14 PM Eastern

Inhibitor Therapeutics EPS Results

Actual EPS
-$0.01
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A

Inhibitor Therapeutics Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Inhibitor Therapeutics Announcement Details

Quarter
Time
N/A
Conference Call Date
N/A
Conference Call Time
N/A

Upcoming Earnings

Inhibitor Therapeutics' next earnings date is estimated for Monday, May 12, 2025, based on past reporting schedules.

Conference Call Resources

Inhibitor Therapeutics Earnings Headlines

Trump’s Secret Social Security Plan?
In less than a decade, Social Security could be out of money. But a surprising plan from Trump’s inner circle may not just save the system — it could unlock a major opportunity for savvy investors. Financial insider Jim Rickards calls it “Social Prosperity,” and says those who act now could see the biggest gains.
Indaptus Therapeutics initiates Phase 1 study of Decoy20
See More Inhibitor Therapeutics Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Inhibitor Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Inhibitor Therapeutics and other key companies, straight to your email.

About Inhibitor Therapeutics

Inhibitor Therapeutics (OTCMKTS:INTI), a pharmaceutical development company, develops and commercializes therapeutics for patients with certain cancers and non-cancerous proliferation disorders in the United States. The company engages in the development of therapies for prostate and lung cancer utilizing itraconazole; and conducted a positive Phase 2b clinical trial of SUBA-Itraconazole for the treatment of basal cell carcinoma nevus syndrome. It has license agreement with Johns Hopkins University. The company was formerly known as HedgePath Pharmaceuticals, Inc. and changed its name to Inhibitor Therapeutics, Inc. in August 2019. Inhibitor Therapeutics, Inc. was founded in 1992 and is based in Tampa, Florida. Inhibitor Therapeutics, Inc operates as a subsidiary of Mayne Pharma Ventures Pty Ltd.

View Inhibitor Therapeutics Profile

More Earnings Resources from MarketBeat